March 26, 2026 by Mohr Marketing
The Digital Edge for Uber and Lyft Assault Lawsuits: How Data Helps Your Uber Sexual Assault Clients Win In rideshare assault litigation, the difference between a difficult case and a dominant one often comes down to what is hiding in the data. While a survivorβs testimony is the heart of the story, digital proof is…
Continue reading Digital Evidence in Uber and Lyft Assault Lawsuits
March 16, 2026 by Mohr Marketing
Safeguarding Your Firmβs Depo-Provera (MDL 3140) Inventory As the pharmaceutical liability landscape shifts toward MDL 3140 (In re: Depo-Provera Products Liability Litigation), many firms are facing a critical operational choice: build volume quickly or build volume correctly. While the potential plaintiff pool for Depo-Provera is massiveβestimated at 74 million women worldwideβthe clinical criteria required to…
Continue reading Building Your MDL 3140 Portfolio with Precision
March 15, 2026 by Mohr Marketing
Donβt settle for “intake noise.” Leverage our Compliance Shield protocol to acquire signed plaintiffs with 12+ months of usage and imaging-confirmed Intracranial Meningiomas. The Opportunity: Why Pfizer (MDL 3140) Now? Massive Solvency: Unlike other defendants, Pfizer holds immense liquidity, ensuring the “muscle” to absorb global settlements. Scientific Catalyst: A March 2024 BMJ study revealed a…
Continue reading Build a High-Value Depo-Provera Docket with Verified, Audit-Ready Retainers
March 14, 2026 by Mohr Marketing
Depo-Provera MDL Science-Back Intake: How We Filter for the “5.6x Risk” Cohort The catalyst for the Depo-Provera MDL was a bombshell study published in the British Medical Journal (BMJ) in March 2024. That study didn’t just suggest a link; it identified a specific 5.6-fold increased risk of developing meningiomas for women using the drug for…
Continue reading Depo-Provera MDL – How We Filter for the “5.6x Risk” Cohort
March 13, 2026 by Mohr Marketing
The $3B Liquidity Advantage: Why Depo-Provera is the Strategic Play for 2025-2026 As many mass torts face defendants with thinning capital, the Depo-Provera litigation stands out for its defendant solvency. Pfizer holds massive liquidity, providing the “muscle” to absorb a global settlement without the existential risks seen in other recent litigations. A Mature Docket with…
Continue reading Why Depo-Provera is the Strategic Play for 2025-2026
March 12, 2026 by Mohr Marketing
Beyond “Intake Noise”: Why Precision is the Only Way to Build a Depo-Provera Docket The pharmaceutical liability landscape has shifted with the emergence of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the numbers are massiveβan estimated 74 million users worldwideβthe legal viability of these cases hinges on a level of medical precision that…
Continue reading Why Precision is the Only Way to Build a Depo-Provera Docket
March 11, 2026 by Mohr Marketing
MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to…
Continue reading Defendant Solvency and the Business Case for MDL 3140
February 19, 2026 by Mohr Marketing
Mohr Marketing Launches “Compliance Shield” Protocol for MDL 3084 Rideshare Litigation, Solving the “MVA Noise” Crisis for Law Firms As the mass tort landscape pivots following the highly anticipated January 13 start of the MDL 3084 (Rideshare Sexual Assault) bellwether trials, Mohr Marketing, LLC has announced the strategic expansion of its specialized lead generation program.…
Continue reading “Compliance Shield” Protocol for MDL 3084 Rideshare Litigation
February 12, 2026 by Mohr Marketing
Is your intake team vetting for “Addiction” or “Negligence”? There is a massive difference in MDL-3166? The rush for Roblox cases is on. With 70 million daily users, the plaintiff pool is enormous. But if youβve bought leads recently, you know the reality: The volume is high. The quality is… mixed. Too many firms are…
Continue reading Is your intake team vetting for “Addiction” or “Negligence”?
February 10, 2026 by Mohr Marketing
Mohr Marketing Launches “Joint Advertising Compliance Program,” Establishing New Integrity Standard for Mass Tort and Personal Injury Acquisition Initiative introduces audit-ready “Chain of Custody” protocols and strict 1-to-1 Consent, directly addressing FRCP Rule 16.1 and rising judicial scrutiny. [Allentown, PA] β [February 9, 2026] β Amidst a landscape of intensifying scrutiny from Multidistrict Litigation (MDL)…
Continue reading New Standard for Mass Tort and Personal Injury Acquisition